Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Core Viewpoint - Adicet Bio, Inc. is set to provide an update on its clinical pipeline and corporate outlook during a conference call and webcast on January 4, 2024 [1] Group 1: Company Overview - Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer [3] - The company is advancing a pipeline of "off-the-shelf" gamma delta T cells, which are engineered with chimeric antigen receptors (CARs) to enhance selective tumor targeting and facilitate both innate and adaptive immune responses for durable activity in patients [3] Group 2: Event Details - The conference call and webcast will take place on January 4, 2024, at 8:00 am ET [1] - Participants can access the live webcast by registering on the company's website, and a confirmation email with a unique passcode will be sent to all registrants [2] - For those wishing to participate via telephone, a domestic number (888-788-0099) and an international number (312-626-6799) are provided, along with a conference ID [2] - An archived replay of the presentation will be available for 30 days following the event [2]